(1986). A: Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. Embo J
(1985). Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.
(1990). AJ: Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell
(2001). Allday MJ: Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death.
(1989). An intricate route to immortality. Cell
(1993). Baeuerle PA: Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus. Embo J
(1999). D'Erme M: Interactions of Epstein-Barr Virus Origins of Replication with Nuclear Matrix in the Latent and in the Lytic Phases of Viral Infection. Virology
(2002). E: Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBVtransformed B lymphocytes. Oncogene
(1988). E: Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.
(1993). E: Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules. Immunol Lett
(2007). E: LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol
(2001). Epstein Barr Virus
(2008). Epstein-Barr virus induces an oxidative stress during the early stages of infection in B lymphocytes, epithelial, and lymphoblastoid cell lines. Mol Cell Biochem
(1996). Expression of the Epstein Barr Virus Transforming
(2004). High physiological levels of LMP1 result in phosphorylation of eIF2 alpha in Epstein-Barr virus-infected cells.
(1979). Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology
(1993). Ischiropoulos H: Evaluation of 2',7'-Dichlorofluorescin and
(1999). Klyubin IV: Roles of reactive oxygen species: signaling and regulation of cellular functions. Int Rev Cytol
(2003). Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.
(1999). LS: Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production.
(2007). Mattia E: Inhibition of Poly(ADPribose)polymerase impairs Epstein Barr Virus lytic cycle progression. Infect Agent Cancer
(2004). Oxygen free radicals and redox biology of organelles. Histochem Cell Biol
(1988). PJ: Sequence analysis of Raji Epstein-Barr virus DNA. Virology
(1996). Raab-Traub N: Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.
(1998). Raab-Traub N: Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice.
(2005). Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. PNAS
(2001). Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem
(2005). Regulation of Survivin and CDK4 by Epstein-Barr virus encoded latent membrane protein 1 in nasopharyngeal carcinoma cell lines. Cell Res
(1991). Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell
(1992). Rickinson AB: Epstein-Barr virus infection and replication in a human epithelial cell system. Nature
(1994). Rickinson AB: Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers.
(2004). Sairenji T: Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells.
(2000). Sato H: Transformation of MadinDarby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene
(2002). Signaling and proapoptotic functions of transformed cell-derived reactive oxygen species. Prostaglandins Leukot Essent Fatty Acids
(2003). Sugden B: CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal
(2003). Sun R: NF-kappaB inhibits gammaherpesvirus lytic replication.
(2005). Susin SA: Programmed cell death via mitochondria: different modes of dying. Biochemistry (Mosc)
(1989). Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.
(2005). Takada K: Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production.
(1998). Takada K: The truncated form of the Epstein-Barr virus LMP-1 is dispensable or complimentable by the full-length form in virus infection and replication. Virology
(2000). The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation. Oncogene
(1989). The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.
(1986). Y: trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment.
(2004). Yamamoto K: DNA damage responses to oxidative stress. DNA Repair (Amst)
(2001). Young LS: LMP1 structure and signal transduction. Semin Cancer Biol